PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-4.59%
Cash & equivalents declining -4.59% while Biotechnology shows -7.95% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
-40.54%
Short-term investments yoy growth below half the Biotechnology median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
-4.61%
Cash + STI yoy growth 0.5-0.75x the Biotechnology median of -6.46%. Guy Spier would be cautious about potential underfunding of liquidity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.92%
0.75-0.9x the Biotechnology median of -5.85%. John Neff wonders if the firm invests less in working capital or sales growth is slower.
10.64%
PP&E growth ≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.58%
Below half the Biotechnology median of -0.10%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Near the Biotechnology median of -4.52%. Charlie Munger sees typical asset growth among the sector.
-12.14%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half Biotechnology median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-34.95%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-29.36%
Below half Biotechnology median of 2.42%. Joel Greenblatt sees more conservative short-term leverage than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.36%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
3.53%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-3.88%
0.75-0.9x Biotechnology median of -4.32%. John Neff wonders if the firm lags peers in reinvested profits.
-25.46%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-1.65%
Below half Biotechnology median of -5.56%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-4.86%
Near Biotechnology median of -4.62%. Charlie Munger sees standard yoy changes matching sector norms.
-40.54%
Below half Biotechnology median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
4.24%
Below half of Biotechnology median 8.90%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.